Xtalks will be hosting a webinar on June 21, 2024, to explore the impact of artificial intelligence (AI) in the development and engineering of antibody therapeutics. The event will focus on how AI technologies are revolutionising the assessment of antibody developability, offering insights into accelerating the production and efficacy of monoclonal antibodies (mAbs) for clinical applications.
AI-Powered Approaches to Antibody Therapeutics Developability to be Discussed in Upcoming Webinar
A webinar focusing on the role of artificial intelligence (AI) in the developability assessment and engineering of antibody therapeutics will be hosted by Xtalks on June 21, 2024. The event seeks to shed light on how AI can streamline the development process for monoclonal antibodies (mAbs), making them safer and more effective for clinical use.
Antibodies, particularly mAbs, have taken on a pivotal role in modern medicine, with more than 100 therapeutic antibodies currently available on the market. These antibodies are used to treat a variety of diseases due to their ability to specifically target and neutralise pathogens. However, creating these antibodies is not a straightforward process. One of the critical challenges in their development is ensuring their “developability,” which refers to the potential of an antibody candidate to be successfully produced, scaled up, and used as a safe and effective drug.
Historically, the assessment of developability involves a meticulous examination of an antibody’s properties at early stages to avoid costly failures later on. Contract Research and Manufacturing Organizations (CRMOs) often conduct this developability assessment to ensure that candidates can progress through chemistry, manufacturing, and control (CMC) processes without excessive costs or delays.
AI technologies are now increasingly being employed in this domain, transforming bioinformatics research and applications, especially in protein and antibody analysis fields. These AI-based platforms facilitate early-stage screening by evaluating crucial parameters such as immunogenicity, viscosity, aggregation, degradation, and post-translational modifications (PTMs).
The upcoming webinar will feature Carter Hao, a Senior Bioinformatics Scientist at GenScript, who will present on the Immunoinformatics Comprehensive Service Platform. This AI-based tool is designed to assess various attributes pertinent to the developability of antibody therapeutics. The discussion will encompass the technological solutions that AI brings to the table, including antibody engineering services like humanization, caninization, and felinization.
Additionally, case studies will be showcased to illustrate the practical applications of these technologies in antibody developability assessment. Attendees will have the opportunity to engage in a Q&A session with Hao, addressing any specific questions they might have concerning the integration of AI in antibody development.
According to experts, leveraging AI for developability assessments could potentially reduce the time and cost associated with bringing therapeutic antibodies to market. This could have significant implications for the pharmaceutical industry, enabling faster development cycles and more efficient production pipelines.
The webinar will be open to participants worldwide and will take place on Friday, June 21, 2024, at 10 am EDT (3 pm BST/UK). Interested individuals can register through the Xtalks website to secure a spot and gain access to the insights provided.
Xtalks is an educational platform that offers webinars and digital content aimed at professionals in the life sciences, healthcare, food, and medical device industries. The organisation, powered by Honeycomb Worldwide Inc., strives to keep industry practitioners informed about the latest developments, regulations, and trends.
For more information or to register for the event, individuals can visit the Xtalks website. The event promises to deliver valuable knowledge on the intersection of AI and antibody therapeutics, reflecting a growing trend towards the digital transformation of biopharmaceutical research.
